Identification of HCV Inhibitors from a Cell-Based Sub-Genomic Replicon Screen

David C. Pryde, Thien-Duc Tran, Mark Gardner, Chris Pickford, Stephen M. Shaw, Mike Westby, Tanya Parkinson, Caroline Smith-Burchnell, Rob Webster, Satish Dayal

Anti-Infectives Research Unit, Pfizer Global Research and Develoapment, Sandwich, UK.
Anti-Infectives Research Unit, Pfizer Global Research and Development, Sandwich, UK.
Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich, UK.
Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Sandwich, UK.

DOI: 10.4236/ojmc.2013.31003                

Abstract

A high throughput screen of the Pfizer compound collection was carried out using a hepatitis C virus (HCV) genotype 1b subgenomic replicon cell line. Those confirmed hits that demonstrated broad spectrum activity without overt cytotoxicity were further evaluated, leading to the identification of a series of pyrrolopyridines with excellent antiviral activity in a fully infectious HCV cell-based assay and pharmacokinetic properties.

Keywords

HCV; Replicon; Antiviral; Cell-Based Screen

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	D. Lavanchy, “The Global Burden of Hepatitis C,” Liver International, Vol. 29, Suppl. 1, 2009, pp. 74-81. doi:10.1111/j.1478-3231.2008.01934.x
[2]	R. S. Brown, “Hepatitis C and Liver Transplantation,” Nature, Vol. 436, No. 7035, 2005, pp. 973-978. doi:10.1038/nature04083
[3]	J. H. Hoofnagle and L. B. Seeff, “Targeting the NonStructural Proteins of Hepatitis C Virus: Beyond Hepatitis C Virus Protease and Polymerase,” The New England Journal of Medicine, Vol. 355, 2006, pp. 2444-2451. doi:10.1056/NEJMct061675
[4]	S. J. Hadziyannis, H. Sette, T. R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer, D. Bernstein, M. Rizzetto, S. Zeuzem, P. J. Pockros, A. Lin and A. M. Ackrill, “Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose,” Annals of Internal Medicine, Vol. 140, No. 5, 2004, pp. 346-355.
[5]	S. M. Lemon, J. A. McKeating, T. Pietschmann, T. L. Tellinghuisen, D. N. Frick, J. S. Glenn, J. Symons and P. A. Furman, “Development of Novel Therapies for Hepatitis C,” Antiviral Research, Vol. 86, No. 1, 2010, pp. 79-92. doi:10.1016/j.antiviral.2010.02.003
[6]	L. S. Smith, M. Nelson, S. Naik and J. Woten, “Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C,” The Annals of Pharmacotherapy, Vol. 45, No. 5, 2011, pp. 639-648. doi:10.1345/aph.1P430
[7]	K. X. Chen and G. F. Njoroge, “1—The Journey to the Discovery of Boceprevir: An NS3-NS4 HCV Protease Inhibitor for the Treatment of Chronic Hepatitis C,” Progress in Medicinal Chemistry, Vol. 49, 2010, pp. 1-36. doi:10.1016/S0079-6468(10)49001-3
[8]	P. L. Beaulieu, “Filibuvir, a Non-Nucleoside NS5B Polymerase Inhibitor for the Potential Oral Treatment of Chronic HCV Infection,” IDrugs, Vol. 13, No. 12, 2010, pp. 938-948.
[9]	R. A. Fridell, D. Qiu, L. Valera, C. Wang, R. E. Rose and M. Gao, “Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052,” Journal of Virology, Vol. 85, No. 14, 2011, pp. 7312-7320. doi:10.1128/JVI.00253-11
[10]	T. P. Holler, T. Parkinson and D. C. Pryde, “Targeting the Non-Structural Proteins of Hepatitis C Virus: Beyond Hepatitis C Virus Protease and Polymerase,” Expert Opinion on Drug Discovery, Vol. 4, No. 3, 2009, pp. 293-314. doi:10.1517/17460440902762802
[11]	Genotype 1b (Con1, Licensed from Reblikon GmbH) HCV Replicon Cells Were Resuspended to a Concentration of 1.4 × 105 Cells/ml by Addition of Pre-Warmed Medium (DMEM + 10% FCS). 45 μl of This Suspension Was Added to Each Well a 384-Well Assay Plate (Lumitrac, Greiner) Already Containing 0.5 l of Test Compound. All Plates Were Covered with gas Permeable Seals and Incubated at 37oC, 5% CO2 for 48 Hours. After 48 Hours, the Plate Was Removed from the Incubator and Left to Cool to Room Temperature for 15 -30 mins. An Equal Volume of Reconstituted Lyophilised Britelite plus Substrate (PerkinElmer) to Medium Was Added to Each Well. Luminescence Was Read Immediately on an EnVision (Perkin Elmer) Plate Reader.
[12]	1[2-(4-Iodophenyl)-3-(4-Nitrophenyl)-5-(2,4-Disulfophenyl)-2H-Tetrazolium], CAS Registry Number, 150849-52-8.
[13]	Genotype 1b (Con1) HCV Replicon Cells Were Resuspended to a Concentration of 1.4 × 105cells/ml by Addition of Pre-Warmed Medium (DMEM +10% FCS). 45 μl of This Suspension Was Added to Each Well of a 384-Well Assay Plate (Greiner) Already Containing 0.5 l of Test Compound. All Plates Were Covered with Gas Permeable Seals and Incubated at 37oC, 5% CO2 for 48 Hours. After 48 Hours, 5 μl of WST-1 Cell Proliferation Reagent (Roche) Was Added to Each Well and the Plate Returned to the Incubator for 1 Hour. After This Incubation Period Absorbance Was Read at 450 nm on an EnVision (Perkin Elmer) Plate Reader.
[14]	Genotype 1a (H77, Licensed from Apath LLC) HCV Replicon Cells Were Resuspended to a Concentration of 1.4 × 105 Cells/ml by Addition of Pre-Warmed Assay Medium (DMEM + 10% FCS). 45 μl of This Suspension Was Added to Each Well of a 384-Well Assay Plate (Lumitrac, Greiner), Already Containing 0.5 l of Test Compound. All Plates Were Covered with Gas Permeable Seals and Incubated at 37oC, 5% CO2 for 48 Hours. After 48 Hours, the Assay Plate Was Removed from the Incubator and Left to Cool to Room Temperature for 15-30 mins. Medium Was Removed from the Wells and 5 μl Lysis Buffer (Renilla Luciferase Assay Kit, Promega) Was Added to Each Well. The Plate Was Incubated at Room Temperature on a Rocker for 15 mins then 15 μl Assay Substrate was Added to Each Well. Luminescence Was Read Immediately Using an EnVision Plate Reader.
[15]	Details of the Biochemical Assays and compound Screening within Them Will Be Described Elsewhere.
[16]	J. Blagg, C. Mowbray, D. C. Pryde, G. Salmon, E. Schmid, D. Fairman and K. Beaumont, “Small, NonPeptide C5a Receptor Antagonists: Part 1,” Bioorganic & Medicinal Chemistry Letters, Vol. 18, 20, 2008, pp. 5601-5604. doi:10.1016/j.bmcl.2008.08.106
[17]	J. Blagg, C. Mowbray, D. Pryde, G. Salmon, D. Fairman, E. Schmid and K. Beaumont, “Small, Non-Peptide C5a Receptor Antagonists: Part 2,” Bioorganic & Medicinal Chemistry Letters, Vol. 18, No. 20, 2008, pp. 5605-5608. doi:10.1016/j.bmcl.2008.08.101
[18]	M. P. Edwards and D. A. Price, “Chapter 23—Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks,” Annual Reports in Medicinal Chemistry, Vol. 45, 2010, pp. 380-391. doi:10.1016/S0065-7743(10)45023-X
[19]	5-(2-Thienyl)-N-(2-Thienylmethyl)-7-(Trifluoromethyl)-pyrAzolo[1,5-a]Pyrimidine-2-Carboxamide, CAS Registry Number 314049-21-3.
[20]	For the Weak Inhibition of Myc/Max Transcription Factors by Structurally Similar Compounds See A. Kiessling, B. Sperl, A. Hollis, D. Eick and T. Berg, “Selective Inhibition of c-Myc/Max Dimerization and DNA Binding by Small Molecules,” Chemistry & Biology, Vol. 13, No. 7, 2006, pp. 749-751. doi:10.1016/j.chembiol.2006.05.011
[21]	S. K. Chunduru, C. A. Benetatos, T. J. Nitz and T. R. Bailey, “Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases,” US Patent No. US2004039533, 2005.
[22]	G. Koutsoudakis, A. Kaul, E. Steinmann, S. Kallis, V. Lohmann, T. Pietschmann and R. Bartenschlager, “Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses,” Journal of Virology, Vol. 80, No. 11, 2006, pp. 5308-5320. doi:10.1128/JVI.02460-05
[23]	B. Feng, J. B. Mills, R. E. Davidson, R. J. Mireles, J. S. Janiszewski, M. D. Troutman and S. M. de Morais, “In Vitro P-Glycoprotein Assays to Predict the in Vivo Interactions of P-Glycoprotein with Drugs in the Central Nervous System,” Drug Metabolism and Disposition, Vol. 36, No. 2, 2008, pp. 268-275. doi:10.1124/dmd.107.017434
[24]	G. Allan, J. Davis, M. Dickins, I. Gardner, T. Jenkins, H. Jones, R. Webster and H. Westgate, “Pre-Clinical Pharmacokinetics of UK-453,061, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), and Use of in Silico Physiologically Based Prediction Tools to Predict the Oral Pharmacokinetics of UK-453,061 in Man,” Xenobiotica, Vol. 38, No. 6, 2008, pp. 620-640. doi:10.1080/00498250802069088
[25]	K. Finlayson, L. Turnbull, C. T. January, J. Sharkey and J. S. Kelly, “[3H]Dofetilide Binding to HERG Transfected Membranes: A Potential High Throughput Preclinical Screen,” European Journal of Pharmacology, Vol. 430, No. 1, 2001, pp. 147-148. doi:10.1016/S0014-2999(01)01362-0